Segall Bryant & Hamill LLC Has $5.77 Million Holdings in Phibro Animal Health Corporation $PAHC

Segall Bryant & Hamill LLC trimmed its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 13.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,301 shares of the company’s stock after selling 16,328 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.26% of Phibro Animal Health worth $5,769,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Bank of America Corp DE lifted its stake in Phibro Animal Health by 22.6% in the 1st quarter. Bank of America Corp DE now owns 78,957 shares of the company’s stock valued at $4,367,000 after acquiring an additional 14,536 shares in the last quarter. Systematic Alpha Investments LLC acquired a new position in Phibro Animal Health during the first quarter worth $293,000. Amundi bought a new position in Phibro Animal Health in the first quarter valued at $539,000. EverSource Wealth Advisors LLC increased its stake in Phibro Animal Health by 19.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,907 shares of the company’s stock valued at $327,000 after buying an additional 943 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of Phibro Animal Health by 19.9% during the 1st quarter. California State Teachers Retirement System now owns 22,515 shares of the company’s stock worth $1,245,000 after buying an additional 3,735 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Citigroup dropped their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. Finally, Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.50.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the transaction, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 50.13% of the stock is owned by corporate insiders.

Phibro Animal Health Stock Up 2.3%

PAHC stock opened at $37.15 on Tuesday. Phibro Animal Health Corporation has a fifty-two week low of $26.08 and a fifty-two week high of $60.08. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 0.51 and a beta of 0.46. The business’s fifty day moving average price is $32.78 and its two-hundred day moving average price is $43.15.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities analysts anticipate that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Wednesday, September 2nd. Phibro Animal Health’s payout ratio is 20.60%.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.